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While opioids are the most effective and widely used class of drug for the management of 
moderate to severe pain, their use may be limited by adverse effects that are unpleasant 
and potentially dangerous. Research is increasingly directed towards strategies to improve 
the use of opioids in pain management, investigating methods by which the analgesia 
afforded by an opioid may be enhanced, while minimising adverse effects. One approach 
that has produced promising findings in animal studies and some clinical reports is the 
combination of an opioid agonist and "ultra-low" (nanomole) doses of an opioid 
antagonist. A recent animal study reported that antinociception may be significantly 
enhanced with the combination of the partial opioid agonist/antagonist buprenorphine and 
ultra-low doses of the antagonist naloxone. The central aim of the studies described herein 
was to investigate the effect of this drug combination on response to experimental 
nociceptive stimuli and the incidence and severity of adverse effects among healthy 
volunteers. 
The first study established normative responses to two commonly used nociceptive tests, 
the cold pressor and electrical stimulation tests, in 100 healthy volunteers. The effect of 
buprenorphine on nociceptive test performance had not previously been determined, 
therefore a dose-ranging study of buprenorphine was conducted to establish a dose­
response relationship. The subsequent two studies investigated the effect of a range of 
buprenorphine:naloxone IV dose ratios (5:1, 10:1, 12.5:1, 15:1, 20:1 and 25:1) on 
nociception and adverse effects among healthy volunteers. These studies are the first to 
investigate the combination of buprenorphine and ultra-low dose antagonist in humans, 
and the first to assess the agonist:antagonist combination in an experimental model of 
human nociception. Antinociception was significantly enhanced with the combination of 
buprenorphine and naloxone in the 12.5:1 and 15:1 ratios. Moreover, this enhanced 
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antinociception occurred without a simultaneous increase in adverse effects and indeed 
with a reduction in the severity of some effects. An agent that produces greater analgesia 
and reduces adverse effects has the potential to overcome some of the barriers that limit the 
use of opioids in pain management. The current findings indicate that further investigation 
of this drug combination is warranted. 
